Apellis Pharmaceuticals, Inc. Forecast, price target & analysts
Apellis Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation
Apellis Pharmaceuticals, Inc. Classifications & Recommendation:
Apellis Pharmaceuticals, Inc. Price Target
| Target Price | $34.17 |
| Price | $21.47 |
| Potential |
59.15%
register free of charge
|
| Number of Estimates | 21 |
|
21 Analysts have issued a price target Apellis Pharmaceuticals, Inc. 2026 .
The average Apellis Pharmaceuticals, Inc. target price is $34.17.
This is
59.15%
register free of charge
$63.00
193.43%
register free of charge
$18.18
15.32%
register free of charge
|
|
| A rating was issued by 27 analysts: 18 Analysts recommend Apellis Pharmaceuticals, Inc. to buy, 8 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Apellis Pharmaceuticals, Inc. stock has an average upside potential 2026 of
59.15%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 781.37 | 951.34 |
| 97.02% | 21.75% | |
| EBITDA Margin | -20.88% | 11.53% |
| 83.93% | 155.21% | |
| Net Margin | -25.32% | -7.03% |
| 81.00% | 72.24% |
22 Analysts have issued a sales forecast Apellis Pharmaceuticals, Inc. 2025 . The average Apellis Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
11 Analysts have issued an Apellis Pharmaceuticals, Inc. EBITDA forecast 2025. The average Apellis Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
22 Apellis Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Apellis Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.60 | -0.53 |
| 64.04% | 66.88% | |
| P/E | negative | |
| EV/Sales | 2.84 |
22 Analysts have issued a Apellis Pharmaceuticals, Inc. forecast for earnings per share. The average Apellis Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Apellis Pharmaceuticals, Inc....
Current Apellis Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Wells Fargo |
Locked
➜
Locked
|
Locked | Oct 15 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Sep 26 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Aug 04 2025 |
| Raymond James |
Locked
➜
Locked
|
Locked | Aug 01 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Aug 01 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Aug 01 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Aug 01 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Oct 15 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Sep 26 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Aug 04 2025 |
|
Locked
Raymond James:
Locked
➜
Locked
|
Aug 01 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 01 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Aug 01 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Aug 01 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
